VCRENasdaqPharmaceutical PreparationsUS GAAP · USD

Vicore Pharma Holding AB

Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases. The group operates through Vicore Pharma AB and Vicore Pharma US Inc., with its main office in Stockholm and a listed presence in Stockholm and the U.S.

Ask about the company

Business

Share of revenue
Clinical-stage drug candidates70 %

Investigational therapies advanced through preclinical and clinical development.

Discovery research20 %

Early-stage programs and target discovery around ATRAG-based biology.

Research support and internal services10 %

Scientific, development, and business support activities within the group.

Customers

Vicore is not a traditional commercial drug seller; its direct counterparties are primarily hospitals, clinical research sites, CROs, and laboratory partners that support the development program. Ultimate beneficiaries are patients and physicians in severe respiratory and fibrotic diseases, while future commercial buyers would be specialty prescribers and healthcare systems if a candidate is approved.

Clinical research network

Hospitals, clinics, and investigators participating in Vicore-sponsored trials and patient recruitment.

CRO and service partners

External partners providing trial management, scientific services, and development execution.

Research collaborators

Academic and industry partners contributing to discovery and translational science.

Future specialty prescribers

Pulmonologists and specialty centers that would use an approved therapy in severe lung disease.

Strategy

Vicore's strategy centers on advancing buloxibutid through clinical development while building a broader pipeline around ATRAG biology. The company also expands its research foundation and external development capabilities to support later-stage value creation and potential partnering options.

Advance buloxibutid in idiopathic pulmonary fibrosisShort term

Clinical progress is the main value driver for a development-stage biotech company.

Expand the early-stage ATRAG pipelineMedium term

A broader pipeline reduces dependence on one asset and creates long-term platform value.

Strengthen scientific and translational capabilitiesMedium term

Deeper biology and discovery capabilities support better target selection and differentiation.

Geography

Vicore is headquartered in Stockholm, Sweden, and the group includes a U.S. subsidiary for local development and business support. Its operating footprint is tied to clinical and research activity rather than broad commercial manufacturing, so geography mainly reflects where trials, scientific work, and corporate functions are organized.

Risks

Vicore's business is exposed to the high failure rate of pharmaceutical R&D, where most projects do not reach approval and clinical programs can be delayed by efficacy, safety, enrollment, or manufacturing issues. As a development-stage biotech, it also depends on continued funding and execution across a small number of programs, which makes setbacks in any one asset material.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Clinical trial failure or delay1Patient recruitment and site execution risk2Financing and capital intensity3Pipeline concentration4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Clinical trial failure or delayImpact: CriticalLikelihood: Medium

    The lead asset must show efficacy and tolerability in trials before value can be realized.

    Exposure: Buloxibutid and other clinical programs

  2. Patient recruitment and site execution riskImpact: HighLikelihood: High

    Enrollment and trial conduct can slow development timelines and increase costs.

    Exposure: Phase 2b and future respiratory studies

  3. Financing and capital intensityImpact: HighLikelihood: High

    R&D-heavy biotech models consume cash before commercialization and may need repeated funding.

    Exposure: Group funding needs

  4. Pipeline concentrationImpact: HighLikelihood: High

    A limited number of programs makes the company vulnerable to setbacks in one asset.

    Exposure: Buloxibutid and ATRAG discovery

Ask Clarifo about Vicore Pharma Holding AB

Accounting

Judgemental items
R&D accruals and prepaid expenses

The report notes reclassification of accrued R&D balances between prepaid expenses and accrued income for comparability.

Impact: Can change expense timing and balance sheet presentation without altering cash flow.

Intercompany service fees

Parent and subsidiaries invoice each other for business support and R&D services.

Impact: Affects consolidation eliminations and local entity results.

Shareholder contributions

Unconditional contributions from the parent to the subsidiary provide funding support.

Impact: Impacts equity financing presentation rather than operating revenue.

R&D expense recognition

Development-stage companies typically expense most research and development costs as incurred.

Impact: Shapes reported losses and makes period-to-period comparability dependent on trial timing.

Similar listed companies

Publicly listed companies with a comparable business focus.

Viking Therapeutics, Inc.

VKTX · Pharmaceutical Preparations

Vincerx Pharma, Inc.

Pharmaceutical Preparations

Immunocore Holdings plc

IMCR · Biological Products, (No Diagnostic Substances)

aTyr Pharma, Inc

ATYR · Biological Products, (No Diagnostic Substances)

Bicara Therapeutics Inc.

BCAX · Pharmaceutical Preparations

Fulcrum Therapeutics, Inc.

FULC · Pharmaceutical Preparations

Last updated: 28/09/2026